Oral medicinal cannabinoids to relieve symptom burden in the palliative care of patients with advanced cancer: a double-blind, placebo-controlled, randomised clinical trial of efficacy and safety of 1:1 delta-9-tetrahydrocannabinol (THC) and cannabidiol (CBD)

Peer Review reports

Original Submission
12 Oct 2019	Submitted	Original manuscript
6 Feb 2020	Reviewed	Reviewer Report - Kirsty Loudon
21 Mar 2020	Reviewed	Reviewer Report - Caroline Fairhurst
30 Mar 2020	Reviewed	Reviewer Report - Sarah Cockayne
11 May 2020	Author responded	Author comments - Janet Hardy
Resubmission - Version 2
11 May 2020	Submitted	Manuscript version 2
19 May 2020	Reviewed	Reviewer Report - Kirsty Loudon
22 May 2020	Reviewed	Reviewer Report - Sarah Cockayne
8 Jun 2020	Reviewed	Reviewer Report - Caroline Fairhurst
17 Jun 2020	Author responded	Author comments - Janet Hardy
Resubmission - Version 3
17 Jun 2020	Submitted	Manuscript version 3
Publishing
19 Jun 2020	Editorially accepted
6 Jul 2020	Article published	10.1186/s13063-020-04541-6

Back to article page